Article
Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.
Blood - 28 Nov 2024
Reis Edimara S, Buonpane Rebecca, Celik Hamza, Marty Caroline, Lei Angela, Jobe Fatoumata, Rupar Mark, Zhang Yue, DiMatteo Darlise, Awdew Rahel, Ferreira Bianca L, Leffet Lynn, Lu Lu, Rosa Elodie, Evrard Maxime, Trivedi Gaurang, Wass Brittney, Horsey April, He Xin, Covington Maryanne, Volgina Alla, Pasquier Florence, Legros Laurence, Fouquet Guillemette, Vainchenker William, Yang Yan-Ou, Barker Breann, Zhou Jing, Stewart Shaun, Hitchcock Ian S, Dhanak Dashyant, Macarron Ricardo, Plo Isabelle, Nastri Horacio, Mayes Patrick A
Abstract excerpt
ABSTRACT: Mutations in calreticulin (mutCALR) are the second most common drivers of myeloproliferative neoplasms (MPNs) and yet, the current therapeutic landscape lacks a selective agent for mutCALR-expressing MPNs. Here, we show that the monoclonal antibody INCA033989 selectively targets mutCALR-positive cells. INCA033989 antagonized mutCALR-driven signaling and proliferation in engineered cell lines and primary...
Topics
- Animals
- Calreticulin
- Humans
- Mice
- Myeloproliferative Disorders
- Mutation
- Antibodies, Monoclonal